(Total Views: 744)
Posted On: 04/15/2021 1:59:03 PM
Post# of 72446
Ridgeback and Merck halt molnupiravir trial for Covid 19 hospitalized patients.
In addition to announcing the withdrawal of its vaccine and CD24Fc, Merck has also announced Ridgeback and Merck are halting Covid 19 trials for hospitalized patients with oral molnupiravir.
"Early study results on hospitalized patients found that the treatment is unlikely to reduce hospitalization stays and deaths, the companies said Thursday.
Merck said testing found that the drug, called molnupiravir, inhibits replication of the virus. But the trial of people who weren’t hospitalized was too small to show that the drug reduced clinical symptoms during their early treatment, Merck said.
Another surprise Merck announcement today reverses previous optimistic reports of molnupiravirs results for Covid19.
Brilacidin's competitors are dropping like flies.
Farrell
https://www.wsj.com/articles/merck-partner-ha...1618483561
In addition to announcing the withdrawal of its vaccine and CD24Fc, Merck has also announced Ridgeback and Merck are halting Covid 19 trials for hospitalized patients with oral molnupiravir.
"Early study results on hospitalized patients found that the treatment is unlikely to reduce hospitalization stays and deaths, the companies said Thursday.
Merck said testing found that the drug, called molnupiravir, inhibits replication of the virus. But the trial of people who weren’t hospitalized was too small to show that the drug reduced clinical symptoms during their early treatment, Merck said.
Another surprise Merck announcement today reverses previous optimistic reports of molnupiravirs results for Covid19.
Brilacidin's competitors are dropping like flies.
Farrell
https://www.wsj.com/articles/merck-partner-ha...1618483561
(8)
(0)
